SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf ($WULF) is trending amid discussions of a potential short squeeze, fueled by high short interest and recent analyst upgrades, as well as a video highlighting the company's latest data center and AI contract with Google ($GOOG) which some investors believe has caught shorts off guard. The community is closely watching for a breakout above key resistance levels, with many anticipating a significant price increase if short covering begins in earnest, while a sizable financing is being weighed.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending amid discussions about a recent capital raise and its potential impact on the company's future. While some community members express concerns about dilution, others view the oversubscribed offering as a sign of institutional confidence and a potential catalyst for growth in the competitive quantum computing sector. The conversation also includes comparisons to other quantum computing stocks.

"What's Updog?" is a Community Led token.

UpDog

UpDog ($UPDOG) is trending as the community rallies around the joke-inspired Solana token, celebrating its long-term presence and active community. Discussions revolve around its availability on Jupiter Strict List and the potential for new investors to become millionaires by swapping SOL. The UpDog community emphasizes collaboration and shared success, fostering a positive environment.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending due to new AI partnerships with Nvidia, OpenAI, and Snowflake, with the community buzzing about the potential for significant growth and a shift from RPA to broader AI applications. Despite positive news, some traders express frustration over the stock's inability to sustain gains, while others see it as an undervalued gem in the AI sector ready for a major breakout. Discussions also include the company's financials and potential for long-term investment.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter CRYPTO ($JUP) is trending as the community rallies around $UPDOG, a Solana-based token listed on Jupiter's strict list. Community members are actively encouraging others to "load" $UPDOG, highlighting its potential and joke-like nature within the Solana ecosystem, and referencing $BROKE.

Sui is an innovative layer-1 blockchain platform crafted to meet the demands of global adoption, providing a secure, robust, and scalable development environment. Rooted in a unique object-centric data model and fortified by the trusted Move programming language, Sui is engineered to tackle the inefficiencies found in current blockchain frameworks.  In addition to its solid technical underpinnings, Sui places a strong emphasis on user experience, aiming to remove common barriers encountered in blockchain interactions. Through groundbreaking features such as zkLogin, sponsored transactions, and programmable transaction blocks, Sui sets a new standard for user accessibility and friendliness within Web3 applications.  Unique elements of Sui Sui’s innovative architecture ensures swift transactions with stable fees and high throughput through horizontal scaling. Its object-oriented design offers deep composability for developers, enabling tailored object types with network-wide compatibility. This revolutionizes asset and protocol collaboration, fostering product innovation.  The platform's object-oriented approach dramatically improves transaction processing, enabling parallel execution and faster completion times. Additionally, unique consensus requirements expedite transaction finalization while maintaining stability. Sui prioritizes overcoming Web3 adoption barriers, offering native tools like zkLogin and sponsored transactions for wallet onboarding and fee management.  Move integration into Sui's data model combines innovation with security, mitigating common exploits found in smart contract languages. This empowers developers and users with a secure and intuitive platform, accelerating the evolution of Web3 applications.  About the Sui token The SUI token serves four primary functions within the Sui ecosystem: Proof-of-stake participation - Sui implements a delegated proof-of-stake mechanism, rewarding honest behavior by validators and SUI token holders who stake with them. Gas fee payments - SUI tokens cover gas fees for executing transactions and storing data onchain. Application utility - SUI is a versatile asset, integral to various applications within Sui’s ecosystem, including decentralized exchanges, lending platforms, gaming, and more. Governance - The SUI token empowers holders to participate in on-chain voting on significant matters like protocol upgrades and platform changes, shaping the future of Sui.  Additionally, the Sui storage fund ensures fair compensation for validators by distributing stake rewards over time and covering storage costs for previously stored on-chain data. This tokenomic strategy promotes indefinite data storage while maintaining fair compensation for validators, fostering long-term sustainability.

SUI crypto is trending as the community discusses its potential for future growth and its position relative to other layer-1 blockchains like Solana. Recent partnerships and integrations, such as the one with Google, are being viewed as catalysts. Bullish sentiment is building, with some anticipating a breakout and a run toward previous highs.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

CRML is trending amid speculation of a potential U.S. government stake in the company's Greenland rare earths mine, fueled by recent news reports. The community is discussing the potential for a short squeeze and comparing CRML to other government-backed plays. Investors are closely watching the stock's movements and anticipating further news or official confirmation.

Binance Coin is the cryptocurrency of the Binance platform. It is a trading platform exclusively for cryptocurrencies. The name "Binance" is a combination of binary and finance.  Thus, the startup name shows that only cryptocurrencies can be traded against each other. It is not possible to trade crypto currencies against Fiat. The platform achieved an enormous success within a very short time and is focused on worldwide market with Malta headquarters. The cryptocurrency currently has a daily trading volume of 1.5 billion - 2 billion US dollars and is still increasing.  In total, there will only be 200 million BNBs. Binance uses the ERC20 token standard from Ethereum and has distributed it as follow: 50% sold on ICO, 40% to the team and 10% to Angel investors. The coin can be used to pay fees on Binance. These include trading fees, transaction fees, listing fees and others. Binance gives you a huge discount when fees are paid in BNB.   The schedule of BNB fees discount is as follow: In the first year, 50% discount on all fees, second year 25% discount, third year 12.5% discount, fourth year 6.75 % discount, and from the fifth year onwards there is no discount. This structure is used to incentivize users to buy BNB and do trades within Binance.  Binance announced in a buyback plan that it would buy back up to 100 million BNB in Q1 2018. The coins are then burned. This means that they are devaluated to increase the value of the remaining coins. This benefits investors. In the future, the cryptocurrency will remain an asset on the trading platform and will be used as gas.  Other tokens that are issued by exchanges include Bibox Token, OKB, Huobi Token, and more.

Binance

BNB is trending amid discussions about its potential to reach new all-time highs, with some community members setting ambitious targets. Conversations also focus on the Binance ecosystem and its influence on BNB's value, while others compare it to other exchange tokens and projects. Speculation is growing around potential partnerships and listings.

Ecolab, Inc. engages in providing products and services in the field of water, hygiene, and energy. It operates through the following segments: Global Industrial, Global Institutional and Specialty, Global Healthcare and Life Sciences, Global Pest Elimination, and Corporate. The Global Industrial segment relates to water, food and beverage, paper, and downstream operating segments. The Global Institutional and Specialty segment refers to the institutional, specialty, and healthcare operating segments. The Global Healthcare and Life Sciences segment includes the healthcare and life sciences operations. The Global Pest Elimination segment provides services designed to detect, prevent and eliminate pests, such as rodents and insects, in full-service and quick-service restaurants, food and beverage processors, hotels, grocery operations, and other. The company was founded by Merritt J. Osborn in 1923 and is headquartered in St. Paul, MN.

Ecolab, Inc.

Ecolab ($ECL) is trending due to increased options activity and bullish sentiment, with many traders focusing on call options expiring in 2025 and 2026. Community discussion highlights the company's stability as a global leader in cleaning and sanitation, especially when compared to smaller, more speculative plays in the sector. Some analysts point to strong demand for clean energy solutions as a potential growth driver for Ecolab.

Epsium Enterprise Ltd. operates as a holding company, which engages in import trading and distribution of wines and spirits. It offers a range of products, including Chinese liquor, French cognac, Scottish whisky, fine wines, champagne, and other miscellaneous alcoholic beverages. Its brands include Moutai, Xijiu, Wuliangye, Remy Martin Cognac, Macallan, Cointreau, Piper Heidsieck Champagne, French Fine Wines, Red and White Wines. The company was founded by Son I Tam on March 24, 2020 and is headquartered in Macau.

Epsium Enterprise Ltd. - Ordinary Shares - Class A

Epsium Enterprise Ltd.

Epsium Enterprise Ltd. ($EPSM) is trending due to significant volatility and mentions across various trading communities, with discussions ranging from pump-and-dump accusations to short squeeze potential. Community members are actively debating its overnight performance, with some anticipating a morning dump while others set high price targets, contributing to the stock's high volume and price fluctuations. The stock is also being mentioned alongside other volatile tickers and recent IPOs, further fueling its trending status.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results

Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.

Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.

All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy

Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?

The mean of analysts' price targets for Immunovant (IMVT) points to a 137.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus 

Shares of Immunovant, Inc. (IMVT) traded 2% higher on Thursday morning after the company reported a narrower-than-expected first-quarter loss.The clinical-stage immunology company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.immunovant.com/investors/news-events/press-releases/detail/73/immunovant-provides-corporate-updates-and-reports-financial">reported</a> a net loss of $0.64 per share for the quarter compared to a loss of $0.52 for the corresponding quarter of 2024, and lower than an estimated loss of $0.72 per share, as per Finchat data.The company’s increased research and development expenses, as well as general and administrative expenses, weighed on its bottom line, with the net loss widening to $106.45 million.Immunovant is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.Its candidate IMVT-1402 is being developed for the treatment of multiple illnesses, including Graves’ disease (GD), difficult-to-treat Rheumatoid Arthritis (D2T RA), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Sjögren’s Disease (SjD).The company ended the quarter with cash and cash equivalents totalling approximately $714 million, expected to provide runway till 2027.Last month, Immunovant announced changes to its leadership as part of its parent company, Roivant, increasing operational involvement and strategic oversight of the company.The company appointed Eric Venker as CEO, replacing Pete Salzmann, and Tiago Girao as CFO, replacing Renee Barnett.On Stocktwits, retail sentiment around IMVT stayed within the ‘neutral’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_29_at_10_09_02_AM_png_50dfeaa22a.webp" alt="IMVT's Sentiment Meter and Message Volume as of 10:10 a.m. ET on May 29, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>IMVT's Sentiment Meter and Message Volume as of 10:10 a.m. ET on May 29, 2025 | Source: Stocktwits</figcaption></figure> According to data from Koyfin, 12 of the 15 analysts covering Immunovant rate it a ‘Buy’ or higher, while three rate it a ‘Hold’. The stock has an average price target of $45.15, representing an upside of over 200% from its current share price.<a href="https://stocktwits.com/symbol/IMVT">IMVT stock</a> is down by about 43% this year and by about 51% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/iridium-partners-with-syniverse-to-launch-global-satellite-service/ch0AYoSRbto">Iridium Partners With Syniverse To Launch Global Satellite Service: Retail Stays Confident</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence

The clinical-stage immunology company reported a net loss of $0.64 per share for the quarter, lower than an estimated loss of $0.72 per share.

Equity

Immunovant, Inc. (IMVT) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.immunovant.com/investors/news-events/press-releases/detail/72/immunovant-announces-next-phase-of-growth-with-roivant">announced</a> on Monday that Roivant President Eric Venker will succeed Pete Salzmann as the new CEO, following Salzmann's retirement from his role.Venker, meanwhile, will continue to serve on Immunovant’s Board of Directors.Tiago Girao will be the company’s new CFO, replacing Renee Barnett. Girao was formerly the CFO of biopharmaceutical company Telavant Holdings.Immunovant stated that these changes are part of its parent company, Roivant, increasing operational involvement and strategic oversight of the company.&nbsp; George Migausky has stepped down from the Immunovant board of directors, and Robert Susman and Jacob Bauer have joined the board, effective April 18, 2025, the company added.Immunovant is a clinical-stage immunology company developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.The company now plans to study its IMVT-1402, an anti-FcRn antibody for the treatment of IgG-mediated autoimmune diseases, in the treatment of Sjögren’s disease and Cutaneous Lupus Erythematosus as well. No therapies have been explicitly approved for the treatment of Sjögren’s disease to date, it said.The company said it is beginning to conclude development activities for batoclimab, an anti-FcRn monoclonal antibody.Venker said that Immunovant has shown “compelling efficacy data” in clinical trials for batoclimab in Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Graves’ Disease, and Thyroid Eye Disease.Immunovant said that its current cash balance is expected to provide a runway till 2027.On Stocktwits, retail sentiment around the stock jumped from ‘bearish’ to ‘bullish’ territory while message volume remained at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:644/147;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_21_at_8_09_32_AM_png_03ceffe093.webp" alt="IMVT's Sentiment Meter and Message Volume as of 8:10 a.m. ET on April 21, 2025 | Source: Stocktwits" width="644" height="147"><figcaption>IMVT's Sentiment Meter and Message Volume as of 8:10 a.m. ET on April 21, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/IMVT">IMVT stock</a> is down by over 40% so far this year and by over 45% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-decline-as-trump-tariffs-cloud-earnings-season/chQiK8CRbQg">Dow Futures Decline As Trump’s Tariffs Cloud Earnings Season: Tech Bull Says ‘White House Needs Trade Deals Done Quick’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated

Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic oversight of the company. 

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 24, 2025 NEW YORK, Jan. 24...

What the Options Market Tells Us About Immunovant

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Immunovant Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

IMVT
Immunovant Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IMVT News

IMVT Immunovant Inc